Press release
Gastrointestinal Stromal Tumor Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceutical
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Gastrointestinal Stromal Tumor pipeline constitutes 25+ key companies continuously working towards developing 28+ Gastrointestinal Stromal Tumor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Gastrointestinal Stromal Tumor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastrointestinal Stromal Tumor Market.
The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report: https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gastrointestinal Stromal Tumor treatment therapies with a considerable amount of success over the years.
• Gastrointestinal Stromal Tumor companies working in the treatment market are IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., Cogent Biosciences, Ascentage Pharma Group, Daiichi Sankyo Company, and others, are developing therapies for the Gastrointestinal Stromal Tumor treatment
• Emerging Gastrointestinal Stromal Tumor therapies in the different phases of clinical trials are- IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, PLX9486, Nilotinib, HQP1351, DS 6157, and others are expected to have a significant impact on the Gastrointestinal Stromal Tumor market in the coming years.
• In June 2022, The US Food and Drug Administration (FDA) gave Immunicum AB's ilixadencel an Orphan Drug Designation (ODD) for the management of Gastrointestinal Stromal Tumours (GIST)
• In January 2022, A Phase III open-label, multinational, multicenter research of CGT9486 in conjunction with sunitinib was started by Cogent Biosciences, Inc. There will be about 426 patients enrolled in this multi-part trial.
• The selective tyrosine kinase inhibitor PLX9486 is intended to effectively inhibit D816V and other KIT exon 17 mutations. It is challenging to obtain wide therapeutic KIT inhibition since the majority of patients with imatinib-resistant GIST have both primary and secondary KIT mutations, frequently including secondary mutations on exon 17 and exon 13. In the first half of 2023, Cogent Biosciences, Inc. will present preliminary findings from PEAK, a registrational randomised, open-label, international Phase III clinical trial for patients with gastrointestinal stromal tumours (GIST)
• In June 2022, The third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351) was studied in a Phase Ib/II research in patients with metastatic gastrointestinal stromal tumours (GIST) who had either failed or been resistant to earlier TKI treatment. The results were released by Ascentage Pharma. Olverembatinib (HQP1351), according to the manufacturer, showed encouraging anticancer efficacy in patients with gastrointestinal stromal tumours (GIST) that were resistant to tyrosine kinase inhibitors (TKIs) but low in succinate dehydrogenase (SDH). Olverembatinib will be jointly developed and commercialised in the Chinese cancer market by Ascentage Pharma and Innovent Biologics (1801.HK) beginning in July 2021
• In January 2022, The lead candidate, THE-630, is being evaluated in patients with advanced gastrointestinal stromal tumours (GIST) in Theseus' current Phase I/II research, according to a statement from the company. The first data set is anticipated in 1H 2023. The company's flagship candidate THE-630 was given orphan drug designation (ODD) by the US Food and Drug Administration in February 2022 for the treatment of patients with advanced gastrointestinal stromal tumours (GIST)
• In August 2021, Bezuclastinib/CGT9486 received orphan drug designation from the FDA for use in gastrointestinal stromal tumours.Bezuclastinib was given orphan drug status by the FDA for the treatment of GIST, which is thought to affect between 4,000 and 6,000 people annually in the United States.
Gastrointestinal Stromal Tumor Overview
The uncommon cancer known as a gastrointestinal stromal tumour (GIST) affects the abdomen's digestive system or surrounding structures. Interstitial cells of Cajal (ICCs), less differentiated stem cells, or precursor cells that can grow into ICCs are the sources of this sarcoma.
Get a Free Sample PDF Report to know more about Gastrointestinal Stromal Tumor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Gastrointestinal Stromal Tumor Drugs Under Different Phases of Clinical Development Include:
• IDRX-42: IDRx, Inc
• THE-630: Theseus Pharmaceuticals
• PDR001: Novartis
• Crenolanib: Arog Pharmaceuticals, Inc.
• Famitinib: Jiangsu HengRui Medicine Co., Ltd.
• CGT9486: Cogent Biosciences, Inc.
• PLX9486: Cogent Biosciences
• Nilotinib: Novartis
• HQP1351: Ascentage Pharma Group
• DS 6157: Daiichi Sankyo Company
Gastrointestinal Stromal Tumor Route of Administration
Gastrointestinal Stromal Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Gastrointestinal Stromal Tumor Molecule Type
Gastrointestinal Stromal Tumor Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment
• Gastrointestinal Stromal Tumor Assessment by Product Type
• Gastrointestinal Stromal Tumor By Stage and Product Type
• Gastrointestinal Stromal Tumor Assessment by Route of Administration
• Gastrointestinal Stromal Tumor By Stage and Route of Administration
• Gastrointestinal Stromal Tumor Assessment by Molecule Type
• Gastrointestinal Stromal Tumor by Stage and Molecule Type
DelveInsight's Gastrointestinal Stromal Tumor Report covers around 28+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Gastrointestinal Stromal Tumor product details are provided in the report. Download the Gastrointestinal Stromal Tumor pipeline report to learn more about the emerging Gastrointestinal Stromal Tumor therapies at:
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Gastrointestinal Stromal Tumor Therapeutics Market include:
Key companies developing therapies for Gastrointestinal Stromal Tumor are - Novartis, Bayer, Pfizer, Deciphera Pharmaceuticals, Blueprint Medicines Corporation, Loxo Oncology, Roche, Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc., Cogent Biosciences, Inc., Plexxikon Inc., Theseus Pharmaceuticals, Exelixis, Inc., Ipsen, Bristol-Myers Squibb, Takeda, and others.
Gastrointestinal Stromal Tumor Pipeline Analysis:
The Gastrointestinal Stromal Tumor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
• Gastrointestinal Stromal Tumor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastrointestinal Stromal Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Gastrointestinal Stromal Tumor drugs and therapies-
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gastrointestinal Stromal Tumor Pipeline Market Drivers
• Increasing prevalence of digestive disorders, increasing investment of biotechnology and pharmaceutical industries in research and development, availability of funds is likely to drive the growth of the Gastrointestinal Stromal Tumor are some of the important factors that are fueling the Gastrointestinal Stromal Tumor Market.
Gastrointestinal Stromal Tumor Pipeline Market Barriers
• However, higher cost associated with the treatment procedure and hence, this is a major fact that might be responsible for slowing the market growth, reimbursement Policies and other factors are creating obstacles in the Gastrointestinal Stromal Tumor Market growth.
Scope of Gastrointestinal Stromal Tumor Pipeline Drug Insight
• Coverage: Global
• Key Gastrointestinal Stromal Tumor Companies: IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., Cogent Biosciences, Ascentage Pharma Group, Daiichi Sankyo Company, and others
• Key Gastrointestinal Stromal Tumor Therapies: IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, PLX9486, Nilotinib, HQP1351, DS 6157, and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers
Request for Sample PDF Report for Gastrointestinal Stromal Tumor Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Gastrointestinal Stromal Tumor Report Introduction
2. Gastrointestinal Stromal Tumor Executive Summary
3. Gastrointestinal Stromal Tumor Overview
4. Gastrointestinal Stromal Tumor- Analytical Perspective In-depth Commercial Assessment
5. Gastrointestinal Stromal Tumor Pipeline Therapeutics
6. Gastrointestinal Stromal Tumor Late Stage Products (Phase II/III)
7. Gastrointestinal Stromal Tumor Mid Stage Products (Phase II)
8. Gastrointestinal Stromal Tumor Early Stage Products (Phase I)
9. Gastrointestinal Stromal Tumor Preclinical Stage Products
10. Gastrointestinal Stromal Tumor Therapeutics Assessment
11. Gastrointestinal Stromal Tumor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Gastrointestinal Stromal Tumor Key Companies
14. Gastrointestinal Stromal Tumor Key Products
15. Gastrointestinal Stromal Tumor Unmet Needs
16 . Gastrointestinal Stromal Tumor Market Drivers and Barriers
17. Gastrointestinal Stromal Tumor Future Perspectives and Conclusion
18. Gastrointestinal Stromal Tumor Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Gastrointestinal Stromal Tumor Market https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Gastrointestinal Stromal Tumor Epidemiology https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products
Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastrointestinal Stromal Tumor Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceutical here
News-ID: 3144152 • Views: …
More Releases from DelveInsight Business Research

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…

Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…

Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…

Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Gastrointestinal
Prominent Gastrointestinal Pathogen Testing Market Trend for 2025: Advancements …
What combination of drivers is leading to accelerated growth in the gastrointestinal pathogen testing market?
The rise in foodborne diseases is expected to drive the growth of the gastrointestinal pathogen testing market. Foodborne diseases, caused by consuming contaminated food or drinks, are on the rise due to changes in food production and distribution, inadequate food safety measures, and climate change. Gastrointestinal pathogen testing helps identify pathogens responsible for foodborne illnesses, aiding…
Major Market Shift in Gastrointestinal Pathogen Testing Industry: Advancements I …
What Is the Forecasted Market Size and Growth Rate for the Gastrointestinal Pathogen Testing Market?
The market size for gastrointestinal pathogen testing has seen a consistent growth lately. Projected to surge from $4.05 billion in 2024 to $4.24 billion in 2025, it is expected to grow at a compound annual growth rate (CAGR) of 4.6%. The growth observed during the historic period can be ascribed to factors such as the amplified…
Gastrointestinal Bleeding Treatment Devices Market Report 2024 - Gastrointestina …
"The Business Research Company recently released a comprehensive report on the Global Gastrointestinal Bleeding Treatment Devices Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Gastrointestinal (GI) Stents Market is Driven by Rising Prevalence of Gastroint …
The Gastrointestinal (GI) Stents Market research report provides an in depth examination of the key factors stimulating market expansion. It also sheds light on the challenges or restraining factors that are poised to hinder industry growth over the forecast timeframe. Growth rate, market share captured, and valuation estimates for each region, segment, and company are documented as well.
View Report - https://www.theinsightpartners.com/reports/gastrointestinal-gi-stents-market/
Gastrointestinal stents are used as an effective alternate to perform…
Gastrointestinal Devices Market Report 2018: Segmentation by Type (Gastrointesti …
Global Gastrointestinal Devices market research report provides company profile for Coloplast, Given Imaging, CONMED, Covidien, Ethicon, Olympus, Boston Scientific and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation…
Global Gastrointestinal Industry Report 2016
Global Gastrointestinal Industry 2016 Market Overview, Size, Share, Trends, Analysis, Technology, Applications, Growth, Market Status, Demands, Insights, Development, Research and Forecast 2016-2020.
The analysts of the global Gastrointestinal market report have taken on the challenge of procuring insightful data from reliable resources and precisely segregating critical market dynamics, given the voluminous amount of information available. Established and novice players in the Gastrointestinal market can secure their position on the cutting edge…